The Indianapolis pharma signed a second deal with an Asian company in as many days. Eli Lilly & Co announced on 20 March that it will pay $56m up front to Chinese biotech Innovent Biologics to collaborate on several oncology compounds.
The deal comes just a day after Lilly inked a collaboration with Korea's Hanmi Pharmaceuticals for $690m to work on...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

